Nadofaragene firadenovec
Gene therapy medication / From Wikipedia, the free encyclopedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer.[1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy.[3]
Quick Facts Gene therapy, Target gene ...
Gene therapy | |
---|---|
Target gene | Interferon alfa-2b |
Clinical data | |
Trade names | Adstiladrin |
Other names | Nadofaragene firadenovec-vncg, Instilidrin, rAd-IFN/Syn3 |
License data | |
Routes of administration | Intravesical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
UNII | |
KEGG |
Close
The most common adverse events including laboratory abnormalities, include increased glucose, instillation site discharge, increased triglycerides, fatigue, bladder spasm, micturition urgency, increased creatinine, hematuria, decreased phosphate, chills, dysuria, and pyrexia.[4]
Nadofaragene firadenovec was approved for medical use in the United States in December 2022.[3][4][5]